- Previous Close
3.3200 - Open
3.3000 - Bid 3.4800 x --
- Ask 3.5000 x --
- Day's Range
3.2600 - 3.5600 - 52 Week Range
0.9493 - 4.6200 - Volume
162,722 - Avg. Volume
206,431 - Market Cap (intraday)
308.513M - Beta (5Y Monthly) 1.23
- PE Ratio (TTM)
-- - EPS (TTM)
-0.3300 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
6.50
Alzinova AB (publ), a biopharmaceutical company, develops immunotherapies treatment for Alzheimer's disease in Sweden. Its lead product candidate is ALZ-101, an active therapeutic oligomer-specific vaccine for the treatment of Alzheimer's disease, which has completed part A of phase 1b study; and ALZ-201, a monoclonal antibody that neutralizes the toxic oligomers. The company is developing a humanized version of ALZ-201 in patients with Alzheimer's disease that is in phase 1 clinical study. The company was incorporated in 2011 and is based in Mölndal, Sweden.
www.alzinova.comRecent News: ALZ.ST
View MorePerformance Overview: ALZ.ST
Trailing total returns as of 12/30/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ALZ.ST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ALZ.ST
View MoreValuation Measures
Market Cap
308.51M
Enterprise Value
287.29M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.03k
Price/Book (mrq)
2.37
Enterprise Value/Revenue
957.62
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-121.42%
Return on Assets (ttm)
-9.45%
Return on Equity (ttm)
-16.02%
Revenue (ttm)
14.92M
Net Income Avi to Common (ttm)
-18.12M
Diluted EPS (ttm)
-0.3300
Balance Sheet and Cash Flow
Total Cash (mrq)
4.99M
Total Debt/Equity (mrq)
0.77%
Levered Free Cash Flow (ttm)
-24.88M